Highlights Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Delayed Nasdaq Other stock markets 01:17:17 22/06/2024 am IST			5-day change	1st Jan Change
38.91 ^USD	+2.34%		-0.20%	-18.51%

14/06	Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating	MT
14/06	Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	14/06	MT
Ultragenyx Pharmaceutical Prices $350 Million Offering	14/06	MT
Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025	13/06	MT
Ultragenyx Pharmaceutical Launches Equity Offering	13/06	MT
Ultragenyx Pharmaceutical Inc. Announces Successful Meeting with the FDA	13/06	CI
Sector Update: Health Care Stocks Ease Late Afternoon	13/06	MT
Sector Update: Health Care	13/06	MT
Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate	12/06	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	12/06	MT
Sector Update: Health Care	12/06	MT
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study	12/06	CI
Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate	12/06	MT
Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia	31/05	CI
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	15/05	MT
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $108.8M	03/05	MT
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	03/05	CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta (OI)	30/04	CI
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	16/04	DJ
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	15/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Highlights

Filters